GangaGen is a biotech company that’s working on bacteriophages, which are viruses that infect and destroy bacteria. The company raised $1.8 million to develop treatments for antibiotic-resistant bacterial infections like pneumonia and MRSA, a skin infection that plagues hospitals.
This is the San Francisco, Calif. company’s first funding round. ATEL Ventures made the investment.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more